FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892616508> ?p ?o ?g. }

• W2892616508 endingPage "449" @default.
• W2892616508 startingPage "442" @default.
• W2892616508 abstract "Duchenne muscular dystrophy (DMD), the most common lethal heritable childhood disease, is caused by mutations in the DMD gene that result in the absence of functional dystrophin protein. Exon skipping mediated by antisense oligonucleotides has recently emerged as an effective approach for the restoration of dystrophin, and skipping of exon 51 of DMD has received accelerated approval. Identifying antisense sequences that can provide the highest possible skipping efficiency is crucial for future clinical applications. Herein, we systematically tested two-step antisense oligonucleotide walks along human DMD exon 53 in order to define sequence-dependent effects of antisense oligonucleotide binding sites in human rhabdomyosarcoma cell lines. The first rough whole-exon 53 walk enabled the identification of a target region, and a second walk of this region was used to determine an optimal antisense oligonucleotide sequence (NS-065/NCNP-01) for exon 53 skipping. This oligonucleotide strongly promoted exon 53 skipping in a dose-dependent manner during pre-mRNA splicing in rhabdomyosarcoma and DMD patient-derived cells, and it restored dystrophin protein levels in patient-derived cells. NS-065/NCNP-01, a phosphorodiamidate morpholino oligomer, appears to be a promising candidate for treating exon 53 skipping, and it is potentially applicable to 10.1% of patients with DMD. Duchenne muscular dystrophy (DMD), the most common lethal heritable childhood disease, is caused by mutations in the DMD gene that result in the absence of functional dystrophin protein. Exon skipping mediated by antisense oligonucleotides has recently emerged as an effective approach for the restoration of dystrophin, and skipping of exon 51 of DMD has received accelerated approval. Identifying antisense sequences that can provide the highest possible skipping efficiency is crucial for future clinical applications. Herein, we systematically tested two-step antisense oligonucleotide walks along human DMD exon 53 in order to define sequence-dependent effects of antisense oligonucleotide binding sites in human rhabdomyosarcoma cell lines. The first rough whole-exon 53 walk enabled the identification of a target region, and a second walk of this region was used to determine an optimal antisense oligonucleotide sequence (NS-065/NCNP-01) for exon 53 skipping. This oligonucleotide strongly promoted exon 53 skipping in a dose-dependent manner during pre-mRNA splicing in rhabdomyosarcoma and DMD patient-derived cells, and it restored dystrophin protein levels in patient-derived cells. NS-065/NCNP-01, a phosphorodiamidate morpholino oligomer, appears to be a promising candidate for treating exon 53 skipping, and it is potentially applicable to 10.1% of patients with DMD." @default.
• W2892616508 created "2018-10-05" @default.
• W2892616508 creator A5000608555 @default.
• W2892616508 creator A5014186217 @default.
• W2892616508 creator A5027732443 @default.
• W2892616508 creator A5030335808 @default.
• W2892616508 creator A5030815223 @default.
• W2892616508 creator A5037636576 @default.
• W2892616508 creator A5064949639 @default.
• W2892616508 creator A5068661720 @default.
• W2892616508 creator A5074650312 @default.
• W2892616508 date "2018-12-01" @default.
• W2892616508 modified "2023-10-17" @default.
• W2892616508 title "NS-065/NCNP-01: An Antisense Oligonucleotide for Potential Treatment of Exon 53 Skipping in Duchenne Muscular Dystrophy" @default.
• W2892616508 cites W1533447420 @default.
• W2892616508 cites W1534252971 @default.
• W2892616508 cites W1963727290 @default.
• W2892616508 cites W1973031195 @default.
• W2892616508 cites W1997490017 @default.
• W2892616508 cites W2018499417 @default.
• W2892616508 cites W2026685059 @default.
• W2892616508 cites W2044851147 @default.
• W2892616508 cites W2052476528 @default.
• W2892616508 cites W2062442451 @default.
• W2892616508 cites W2066950610 @default.
• W2892616508 cites W2081716128 @default.
• W2892616508 cites W2095425188 @default.
• W2892616508 cites W2102807861 @default.
• W2892616508 cites W2110154453 @default.
• W2892616508 cites W2154041187 @default.
• W2892616508 cites W2160692395 @default.
• W2892616508 cites W2234725241 @default.
• W2892616508 cites W2394779802 @default.
• W2892616508 cites W2801424838 @default.
• W2892616508 doi "https://doi.org/10.1016/j.omtn.2018.09.017" @default.
• W2892616508 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6202794" @default.
• W2892616508 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30388618" @default.
• W2892616508 hasPublicationYear "2018" @default.
• W2892616508 type Work @default.
• W2892616508 sameAs 2892616508 @default.
• W2892616508 citedByCount "38" @default.
• W2892616508 countsByYear W28926165082019 @default.
• W2892616508 countsByYear W28926165082020 @default.
• W2892616508 countsByYear W28926165082021 @default.
• W2892616508 countsByYear W28926165082022 @default.
• W2892616508 countsByYear W28926165082023 @default.
• W2892616508 crossrefType "journal-article" @default.
• W2892616508 hasAuthorship W2892616508A5000608555 @default.
• W2892616508 hasAuthorship W2892616508A5014186217 @default.
• W2892616508 hasAuthorship W2892616508A5027732443 @default.
• W2892616508 hasAuthorship W2892616508A5030335808 @default.
• W2892616508 hasAuthorship W2892616508A5030815223 @default.
• W2892616508 hasAuthorship W2892616508A5037636576 @default.
• W2892616508 hasAuthorship W2892616508A5064949639 @default.
• W2892616508 hasAuthorship W2892616508A5068661720 @default.
• W2892616508 hasAuthorship W2892616508A5074650312 @default.
• W2892616508 hasBestOaLocation W28926165081 @default.
• W2892616508 hasConcept C104317684 @default.
• W2892616508 hasConcept C129312508 @default.
• W2892616508 hasConcept C136571751 @default.
• W2892616508 hasConcept C142724271 @default.
• W2892616508 hasConcept C14363569 @default.
• W2892616508 hasConcept C153911025 @default.
• W2892616508 hasConcept C173396325 @default.
• W2892616508 hasConcept C194583182 @default.
• W2892616508 hasConcept C2778256501 @default.
• W2892616508 hasConcept C2778776201 @default.
• W2892616508 hasConcept C2778943923 @default.
• W2892616508 hasConcept C2779030066 @default.
• W2892616508 hasConcept C2780394045 @default.
• W2892616508 hasConcept C2780844630 @default.
• W2892616508 hasConcept C2908938912 @default.
• W2892616508 hasConcept C36823959 @default.
• W2892616508 hasConcept C54355233 @default.
• W2892616508 hasConcept C54458228 @default.
• W2892616508 hasConcept C67705224 @default.
• W2892616508 hasConcept C71924100 @default.
• W2892616508 hasConcept C86803240 @default.
• W2892616508 hasConceptScore W2892616508C104317684 @default.
• W2892616508 hasConceptScore W2892616508C129312508 @default.
• W2892616508 hasConceptScore W2892616508C136571751 @default.
• W2892616508 hasConceptScore W2892616508C142724271 @default.
• W2892616508 hasConceptScore W2892616508C14363569 @default.
• W2892616508 hasConceptScore W2892616508C153911025 @default.
• W2892616508 hasConceptScore W2892616508C173396325 @default.
• W2892616508 hasConceptScore W2892616508C194583182 @default.
• W2892616508 hasConceptScore W2892616508C2778256501 @default.
• W2892616508 hasConceptScore W2892616508C2778776201 @default.
• W2892616508 hasConceptScore W2892616508C2778943923 @default.
• W2892616508 hasConceptScore W2892616508C2779030066 @default.
• W2892616508 hasConceptScore W2892616508C2780394045 @default.
• W2892616508 hasConceptScore W2892616508C2780844630 @default.
• W2892616508 hasConceptScore W2892616508C2908938912 @default.
• W2892616508 hasConceptScore W2892616508C36823959 @default.
• W2892616508 hasConceptScore W2892616508C54355233 @default.
• W2892616508 hasConceptScore W2892616508C54458228 @default.
• W2892616508 hasConceptScore W2892616508C67705224 @default.
• W2892616508 hasConceptScore W2892616508C71924100 @default.

• next